Tobacco Companies Are Cashing In on Zyn's Unstoppable Popularity, Here's How
Walk into any convenience store in America, and you'll see them. Those little white cans, stacked near the register, with their minimalist design and bold colors. They're called Zyn, and they've quietly become one of the most popular nicotine products in the country, maybe the most popular.
Here's the thing, though. Zyn isn't just popular. It's unstoppable. And the people really making money from it? They're not the influencers flashing cans on TikTok. They're the tobacco companies.
Big Tobacco has spent decades watching cigarette sales decline. And for a while, they seemed powerless to stop it. But then came Zyn. And suddenly, the industry had a lifeline.
This isn't just a story about a product. It's a story about how an entire industry reinvented itself, how billions of dollars changed hands, and how a little white pouch became the future of nicotine. Let's dive in.
What Is Zyn and Why Is Everyone Talking About It?
The Little White Pouch That Conquered America
So what exactly is Zyn?
Think of it as a tiny pouch, about the size of a piece of chewing gum, that you tuck between your gum and your upper lip. It's filled with nicotine, flavorings, and plant-based fibers. No tobacco leaves. No smoke. No vapor. Just nicotine.
You pop one in, and over the next 30 to 60 minutes, the nicotine slowly releases into your bloodstream through the lining of your mouth. No spitting required. No smell. No one even knows you're using it.
Zyn comes in two nicotine strengths, 3 milligrams and 6 milligrams, and a variety of flavors including cool mint, cinnamon, citrus, and coffee.
But here's the kicker: Zyn was only introduced to the American market in 2019. That's right. In just a few short years, it went from a niche Swedish product to a cultural phenomenon.
Why It's Different From Everything That Came Before
Traditional tobacco products have a problem. They smell. They produce smoke or spit. They're messy. They're increasingly regulated. And frankly, younger generations just aren't that into them.
Zyn solves all of that. It's discreet. It's convenient. It doesn't produce smoke or vapor. You can use it at work, in a meeting, on a plane, anywhere, really. And because it doesn't contain tobacco leaf, it sidesteps some of the stigma attached to traditional smokeless products.
It's a nicotine product that doesn't feel like a nicotine product. And that, my friends, is exactly why it's taken off.
By the Numbers: Zyn's Unstoppable Growth
Now, let's talk about the numbers. Because honestly? They're staggering.
Market Dominance
Zyn now controls a whopping 66% of the US oral nicotine market. To put that in perspective, that's more than every other nicotine pouch brand combined.
Record-Breaking Shipments
In 2025 alone, Philip Morris shipped 794 million cans of Zyn. That's nearly 800 million little white pouches finding their way into pockets, purses, and mouths across America.
Here's how that breaks down:
- Q1 2025: 223.4 million cans, up more than 50% from the same period in 2024
- Q4 2025: 196 million cans, a 19% increase year over year
- Full-year growth: 36.6% year over year
The Growth Trajectory
And it's not slowing down. Retailers expect the oral nicotine category to grow 19% in 2026. Zyn is leading that charge.
One analyst noted that "retailers expect momentum to continue next year" and that innovation is "overwhelmingly" welcomed by retailers and expected to drive growth.
Global Expansion
Zyn isn't just an American phenomenon anymore. It's now available in 55 countries worldwide. Philip Morris is rolling it out internationally as fast as they can produce it.
The global nicotine pouch market is projected to grow from $6.9 billion in 2025 to over $40 billion by 2033. Zyn is positioned to capture a massive slice of that pie.
The $16 Billion Acquisition That Changed Everything
Here's where the story gets really interesting.
Philip Morris's Big Bet
In 2022, Philip Morris International (PMI), the company behind Marlboro cigarettes, made a move that raised eyebrows across the industry. They agreed to acquire Swedish Match, the Swedish company that created Zyn, for a staggering $16 billion.
At the time, some analysts thought PMI was overpaying. Sixteen billion dollars for a nicotine pouch company? It seemed like a lot.
But PMI's CEO, Jacek Olczak, had a vision. He saw that the future of nicotine wasn't in burning tobacco, it was in smoke-free alternatives.
By November 2022, PMI had secured over 90% ownership of Swedish Match. By early 2023, the acquisition was complete.
Why It Was a Genius Move
Fast forward to today, and that $16 billion looks like one of the smartest acquisitions in tobacco history.
In 2025, PMI's total net revenue topped $40 billion. Smoke-free products, led by Zyn and IQOS, accounted for 41.5% of that, or nearly $17 billion.
Think about that. A product that didn't even exist in the US market five years ago now generates nearly half of the revenue for one of the world's largest tobacco companies.
And the profitability is even more impressive. Smoke-free gross margins exceed 70%, compared to just 30-40% for traditional cigarettes.
"Our business is increasingly smoke-free," Olczak told investors in early 2026.
You can say that again.
From Marlboro to Zyn: The Great Tobacco Pivot
The Economics of Nicotine Pouches
Here's the thing about traditional cigarettes. They're a declining business. Smoking rates have been falling for decades. Governments keep raising taxes. Regulations keep getting tighter. And younger generations? They're just not picking up the habit.
But nicotine? Nicotine is as popular as ever. People still want the buzz. They just don't want the smoke.
Enter Zyn. It gives users the nicotine they crave without the smoke, the smell, or the stigma. And for tobacco companies, it offers something even more valuable: profit margins that put cigarettes to shame.
Competitors Scrambling to Catch Up
Zyn's success hasn't gone unnoticed. Every major tobacco company is now racing to get a piece of the action.
Altria (the company behind Marlboro in the US) is pushing its on! brand hard. In Q2 2025, on! shipments climbed 26.5% year over year to 52.1 million cans. The brand now holds an 8.7% retail share of the US oral tobacco category.
British American Tobacco (BAT) is betting big on Velo. Retailers expect Velo Plus to grow 44% in 2025 and another 33% in 2026.
Turning Point Brands is pushing its FRE and ALP pouch brands. In Q1 2025, their modern oral nicotine pouch sales were up nearly tenfold year over year, generating $22.3 million in revenue.
But here's the reality: nobody is catching Zyn. Not anytime soon.
Zyn's 66% market share gives it an enormous advantage. Retailers dedicate more shelf space to it. Consumers are loyal to it. And Philip Morris has the deep pockets to defend its turf.
The Supply Challenge
One interesting wrinkle: Zyn has actually been supply-constrained. In the first half of 2025, Philip Morris couldn't make enough Zyn to meet demand.
Think about that. They sold 794 million cans in 2025 despite not being able to keep up with demand.
When supply normalizes, those numbers are only going to go up.
How Zyn Went Viral Without Traditional Advertising
The Zynfluencer Phenomenon
Zyn hasn't relied on traditional TV commercials or billboard ads. Instead, it's taken a different path, one that's arguably more effective.
Enter the "Zynfluencers."
On TikTok, a flood of young creators have built followings around Zyn content. They post videos showing themselves using the pouches, making jokes about them, and incorporating them into their daily routines.
These aren't paid endorsements (at least not officially). They're organic content created by users who genuinely enjoy the product. But the effect is the same: Zyn has become a lifestyle brand, not just a nicotine product.
A study by UBC Okanagan researcher Dr. Laura Struik found that TikTok "appears to promote nicotine pouches, particularly the brand Zyn, as a lifestyle rather than a way to quit smoking".
Music Festivals and Exclusive Events
Zyn has also gone heavy on experiential marketing. In April 2025, the brand sponsored an exclusive concert in Denver featuring Grammy-nominated singer Noah Kahan. The concert was for Zyn rewards members only, you had to earn points by buying cans to get tickets.
An Instagram post about the event received over 119,000 likes and was shared over 152,000 times.
Zyn also had a presence at several major UK festivals in 2025, including Wireless Festival, Latitude Festival, and Boardmasters.
The "Lifestyle" Branding
What makes Zyn's marketing so effective is that it doesn't feel like marketing. It feels like culture.
The brand has been framed as "empowering, exclusive and socially desirable," according to Dr. Struik's research. Using Zyn means you're "part of a movement".
"Popular, youth-led social media channels are being used to promote these products as a source of pleasure and indulgence," Dr. Struik says.
This is classic tobacco industry playbook stuff, make the product cool, make it social, make it part of an identity. The difference is that now it's happening on TikTok instead of in magazines.
Is Zyn Really Safer? The Debate Rages On
What the FDA Says
In January 2025, the FDA made a landmark decision: they authorized the marketing of 20 Zyn nicotine pouch products.
The agency reviewed extensive data and found that Zyn products have "substantially lower levels of harmful ingredients compared with combustible cigarettes and most smokeless tobacco products".
But, and this is a big but, the FDA was careful to say this does not mean Zyn is safe.
"To receive marketing authorizations, the FDA must have sufficient evidence that the new products offer greater benefits to population health than risks," said Matthew Farrelly, PhD, director of the Office of Science at the FDA's Center for Tobacco Products.
The agency explicitly stated that authorization "does not mean 'these tobacco products are safe, nor are they "FDA approved"'".
The Youth Concern
The biggest concern about Zyn isn't what it does to adults, it's what it does to kids.
Current use of nicotine pouches among youth and young adults is increasing. Senators Richard Blumenthal and Jeff Merkley have raised concerns about "serious public health risks among youth" and the potential for "harmful uptick in use among youth".
The concern is real. Nicotine is highly addictive, and adolescent brains are particularly vulnerable. A quarter of TikTok users are under age 20, meaning the platform where Zyn is most popular is also the platform where young people are most exposed.
Health Risks
So what are the actual health risks of Zyn?
Nicotine addiction: Zyn carries essentially the same addiction risk as other nicotine products. The body doesn't care whether the nicotine came from a pouch or a cigarette, dependence can form just as quickly.
Oral health issues: Prolonged use can lead to gum recession, tooth decay, harmful mouth bacteria, and oral cancer.
Short-term side effects: Nausea, vomiting, headache, dizziness, and a racing heartbeat are common.
Accidental ingestion: There have been sharp increases in nicotine pouch exposures, with approximately 70% occurring in children under five through unintentional ingestion.
The Harm Reduction Argument
On the other side of the debate is the harm reduction argument.
The basic idea is simple: smoking kills. If nicotine pouches can get smokers to switch to a less harmful product, that's a public health win.
PMI is currently seeking FDA approval to market Zyn as a "modified risk" product. If approved, the company would be able to claim that "using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis".
The FDA is currently reviewing this application. If granted, it would give Zyn an unprecedented competitive advantage.
But critics argue that harm reduction only works if the product is actually used for harm reduction, not as a recreational product for people who never smoked in the first place.
And that's the rub. Most Zyn content on social media doesn't mention smoking cessation at all. It portrays the product as fun, cool, and pleasurable. For many young users, Zyn isn't a tool to quit smoking, it's their first introduction to nicotine.
The Future of Nicotine: What Comes After Zyn?
The Modified Risk Gamble
The biggest near-term catalyst for Zyn is the FDA's modified risk tobacco product (MRTP) review.
If PMI secures MRTP status, they'll be able to market Zyn as a reduced-risk product. That's a massive competitive advantage. Competitors without that designation would be at a significant disadvantage.
But it's not guaranteed. The FDA's review is rigorous, and public health advocates are pushing back hard.
More Competition
Competitors aren't standing still. More brands are entering the space every month. Some are offering higher nicotine strengths, new flavors, and different formats.
But Zyn's first-mover advantage, combined with PMI's deep pockets and FDA authorizations, gives it a moat that will be hard to breach.
Regulation on the Horizon
The regulatory environment is getting tighter. New York is considering a proposed excise tax on nicotine pouches. Other states are likely to follow.
And there's always the possibility of stricter FDA oversight, especially if youth usage continues to climb.
The Bigger Picture
Here's what this all means: the tobacco industry is undergoing its biggest transformation in a century.
Cigarettes aren't going away overnight, PMI still sold plenty of Marlboros in 2025. But the future is clearly smoke-free.
PMI's smoke-free business now accounts for 41% of total net revenues. That number is only going to grow.
"Nicotine pouches remain the fastest-growing US segment," said PMI CFO Emmanuel Babeau.
The companies that figure out how to navigate this transition will thrive. The ones that don't? They'll be left behind.
Final Thoughts
Zyn's popularity isn't an accident. It's the result of a perfect storm: a product that solves real problems for consumers, a marketing strategy that taps into youth culture, and a tobacco company willing to bet billions on the future.
But Zyn also raises uncomfortable questions. Is it really harm reduction if it's hooking a new generation on nicotine? Can we trust tobacco companies to put public health ahead of profits? And what happens when the inevitable regulatory crackdown comes?
One thing is clear: Zyn isn't going away. The little white pouches have reshaped the nicotine landscape, and tobacco companies are cashing in. Whether that's a good thing or a bad thing depends on who you ask.
But for Philip Morris, it's looking like the best $16 billion they ever spent.
What Do You Think?
Have you tried Zyn or other nicotine pouches? Do you think they're a helpful tool for smokers trying to quit, or just another way for Big Tobacco to hook a new generation? Drop a comment below and let us know what you think.
And if you found this article helpful, share it with someone who might benefit from understanding what's really happening with Zyn and the tobacco industry.